Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

[1]  J. Bruix,et al.  Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Lenz,et al.  The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. , 2011, Cancer research.

[3]  Derek Y. Chiang,et al.  MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. , 2011, Gastroenterology.

[4]  J. Issa,et al.  Epigenetics in cancer: what's the future? , 2011, Oncology.

[5]  M. Kudo,et al.  Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma , 2011, Molecular Cancer Therapeutics.

[6]  Haiyang Xie,et al.  Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma , 2010, PloS one.

[7]  Stephanie Roessler,et al.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. , 2010, Cancer research.

[8]  Ming-Shiang Wu,et al.  Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma , 2010, Autophagy.

[9]  M. Esteller,et al.  Epigenetic modifications and human disease , 2010, Nature Biotechnology.

[10]  E. Hahn,et al.  The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[11]  Sabrina Smith,et al.  Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels , 2009, Clinical Cancer Research.

[12]  E. Colado,et al.  The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair , 2009, Leukemia.

[13]  Jeffrey W. Scott,et al.  Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma , 2009, British journal of haematology.

[14]  O. Witt,et al.  HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy. , 2009, Cancer letters.

[15]  P. Atadja.  Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. , 2009, Cancer letters.

[16]  Jessica E. Bolden,et al.  The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. , 2009, Blood.

[17]  D. Saur,et al.  E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. , 2009, Gastroenterology.

[18]  H. Prince,et al.  Clinical Studies of Histone Deacetylase Inhibitors , 2009, Clinical Cancer Research.

[19]  R. Johnstone,et al.  Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. , 2009, Future oncology.

[20]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[21]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[22]  Derek Y. Chiang,et al.  Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.

[23]  E. Wagner,et al.  Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. , 2008, The Journal of clinical investigation.

[24]  J. Bruix,et al.  Molecular targeted therapies in hepatocellular carcinoma , 2008, Hepatology.

[25]  Derek Y. Chiang,et al.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.

[26]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[27]  W. Weichert,et al.  Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo , 2008, Clinical Cancer Research.

[28]  Carsten Denkert,et al.  Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. , 2008, The Lancet. Oncology.

[29]  W. Weichert,et al.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy , 2008, British Journal of Cancer.

[30]  S. Kulp,et al.  Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma , 2007, Hepatology.

[31]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[32]  V. Mazzaferro,et al.  Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.

[33]  V. Mazzaferro,et al.  A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. , 2006, Gastroenterology.

[34]  D. Hallahan,et al.  Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. , 2006, Cancer research.

[35]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[36]  D. Qian,et al.  Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589 , 2006, Clinical Cancer Research.

[37]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[38]  E. Raymond,et al.  [Targeted therapies in hepatocellular carcinoma]. , 2010, Presse medicale.

[39]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[40]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[41]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.